Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 63 Show results per page	View Search Criteria \| Help With Results


1.		Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Active				18 to 75				NIMH				R01 MH071580 DATR A3-NSS, NCT00352885

Last Modified: 2/13/2007 First Published: 1/1/1996


2.		Phase III Randomized Study of Resection With or Without Neoadjuvant and Adjuvant Perilymphatic Interleukin-2 and Adjuvant Radiotherapy in Patients With Previously Untreated Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				75 and under				Other				CNR-9506 EU-95024, NCT00002702

Last Modified: 6/11/2008 First Published: 6/1/1999


3.		Phase III Randomized Study of High-Dose Aldesleukin With or Without gp100 Antigen in Patients With Locally Advanced or Metastatic Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				CCCGHS-NCI-T98-0085 NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682

Last Modified: 7/3/2008 First Published: 11/1/1999


4.		Phase III Randomized Study of High-Dose Versus Standard-Dose Cytarabine During Induction and Interleukin-2 Following Intensive Consolidation and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				15 to 60				Other				EORTC-06991 NCT00004128, GIMEMA-EORTC-06991


5.		Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 75				Other				BRD/04/1-D NCT00200577


6.		M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Not specified				Other				A/100/0402 NCT00477906

Last Modified: 8/23/2008 First Published: 12/1/2001


7.		Phase I/II Study of Immunotherapy With Armed Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Women With Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				WSU-2006-130 NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412

Last Modified: 12/9/2008 First Published: 11/24/2002


8.		Phase I/II Pilot Study of Adoptive Immunotherapy With CD8+ WT1-Specific CTL Clones for Patients With Advanced Myelodysplastic Syndromes (MDS), Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), or Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				75 and under				NCI				FHCRC-1655.00 5430, NCT00052520


9.		Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				20 to 75				Other				27MD02 NCT00154713


10.		The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				pepDCIL2- HMO-CTIL NCT00279058

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute